Grail stock plunges almost 50% after NHS trial misses key goal for Galleri cancer test
Grail shares plunged 49.5% to $51.26 by midday Friday after its NHS-Galleri trial missed the primary endpoint of reducing stage III-IV cancers. The company said it would extend follow-up and submit results to ASCO. Over 10 million shares traded. Galleri’s FDA approval process continues, but analysts flagged uncertainty over insurance coverage.